Vilantal comp 80 mg/12,5 mg Filmdragerad tablett

Pays: Suède

Langue: suédois

Source: Läkemedelsverket (Medical Products Agency)

Achète-le

Ingrédients actifs:

hydroklortiazid; valsartan

Disponible depuis:

Sandoz A/S

Code ATC:

C09DA03

DCI (Dénomination commune internationale):

hydrochlorothiazide; valsartan

Dosage:

80 mg/12,5 mg

forme pharmaceutique:

Filmdragerad tablett

Composition:

valsartan 80 mg Aktiv substans; hydroklortiazid 12,5 mg Aktiv substans

classe:

Apotek

Type d'ordonnance:

Receptbelagt

Domaine thérapeutique:

Valsartan och diuretika

Descriptif du produit:

Förpacknings: Blister, 7 tabletter (plast/Al); Blister, 7 tabletter (Al); Blister, 10 tabletter (Al); Blister, 14 tabletter (Al); Blister, 15 tabletter (Al); Blister, 20 tabletter (Al); Blister, 28 tabletter (Al); Blister, 30 tabletter (Al); Blister, 50 tabletter (Al); Blister, 56 tabletter (Al); Blister, 60 tabletter (Al); Blister, 84 tabletter (Al); Blister, 90 tabletter (Al); Blister, 98 tabletter (Al); Blister, 100 tabletter (Al); Blister, 280 tabletter (Al); Blister, 10 tabletter (plast/Al); Blister, 14 tabletter (plast/Al); Blister, 15 tabletter (plast/Al); Blister, 20 tabletter (plast/Al); Blister, 28 tabletter (plast/Al); Blister, 30 tabletter (plast/Al); Blister, 50 tabletter (plast/Al); Blister, 56 tabletter (plast/Al); Blister, 60 tabletter (plast/Al); Blister, 84 tabletter (plast/Al); Blister, 90 tabletter (plast/Al); Blister, 98 tabletter (plast/Al); Blister, 100 tabletter (plast/Al); Blister, 280 tabletter (plast/Al); Blister, 50 x 1 tabletter, endos (Al); Blister, 50 x 1 tabletter, endos (plast/Al)

Statut de autorisation:

Godkänd

Date de l'autorisation:

2011-04-15

Notice patient

                                PACKAGE LEAFLET: INFORMATION FOR THE USER
VILANTAL COMP 80 MG /12.5 MG FILM-COATED TABLETS
VILANTAL COMP 160 MG /12.5 MG FILM-COATED TABLETS
VILANTAL COMP 160 MG /25 MG FILM-COATED TABLETS
VILANTAL COMP 320 MG /12.5 MG FILM-COATED TABLETS
VILANTAL COMP 320 MG /25 MG FILM-COATED TABLETS
Valsartan/hydrochlorothiazide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if
their signs of illness are the same as yours.

If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects not
listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Vilantal comp is and what it is used for
2.
What you need to know before you take Vilantal comp
3.
How to take Vilantal comp
4.
Possible side effects
5.
How to store Vilantal comp
6.
Contents of the pack and other information
1.
WHAT VILANTAL COMP IS AND WHAT IT IS USED FOR
Vilantal comp film-coated tablets contain two active substances called
valsartan and hydrochlorothiazide. Both
of these substances help to control high blood pressure
(hypertension).

VALSARTAN belongs to a class of medicines known as “angiotensin II
receptor antagonists”, which help to
control high blood pressure. Angiotensin II is a substance in the body
that causes vessels to tighten, thus
causing your blood pressure to increase. Valsartan works by blocking
the effect of angiotensin II. As a
result, blood vessels relax and blood pressure is lowered.

HYDROCHLOROTHIAZIDE belongs to a group of medicines called thiazide
diuretics (also known as “water
tablets”). Hydrochlorothiazide increases urine output, which also
lowers blood pressure.
Vilantal comp is used to treat high blood pressure which is not
adequately controlled by a single substance a
                                
                                Lire le document complet
                                
                            

Résumé des caractéristiques du produit

                                MARKNADSFÖRS EJ FÖR NÄRVARANDE.
_Produktinformation_
                                
                                Lire le document complet
                                
                            

Documents dans d'autres langues

Notice patient Notice patient anglais 18-03-2022
Rapport public d'évaluation Rapport public d'évaluation anglais 21-02-2013